Candel Therapeutics (CADL) vs SL Science (SLBT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Candel Therapeutics (CADL) has outperformed SL Science (SLBT) over the past year, gaining 53.3% versus a loss of 85.3%. SL Science is the larger company by market cap ($858.0 million vs $755.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CADL | SLBT |
|---|---|---|
| Share price | $9.87 | $1.53 |
| Market cap | $755.24M | $857.96M |
| 1-day change | +2.17% | +0.66% |
| YTD return | +70.97% | -85.59% |
| 1-year return | +53.33% | -85.32% |
| 5-year return | -1.73% | — |
| EPS (TTM) | $-1.46 | $-0.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $14.00 | $14.50 |
| 52-week low | $4.35 | $1.42 |
| Distance from 52-week high | -29.50% | -89.45% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +120.36% | — |
| Average volume | 1.21M | 80.48K |
| Shares outstanding | 76.52M | 560.76M |
| Employees | 55 | 14 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CADL has outperformed SLBT by 138.7 percentage points over the past year.
About Candel Therapeutics
CADL stock →Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC).
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 55 employees
About SL Science
SLBT stock →SL Science Holding Limited manufactures cosmetic skin care and scalp care products. The company's products include SL bio's milk-derived exosome essence, SL bio's tangerine-derived extract, and the MilkExo concentrate series.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 14 employees
CADL vs SLBT FAQ
Which is bigger, Candel Therapeutics or SL Science?
SL Science (SLBT) is larger, with a market capitalization of $857.96M compared with $755.24M for Candel Therapeutics (CADL).
Which stock has performed better over the past year, CADL or SLBT?
CADL returned +53.33% over the past 12 months, compared with -85.32% for SLBT (price return, excluding dividends). Past performance does not predict future results.
Are Candel Therapeutics and SL Science in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.